期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 79, 期 2, 页码 -出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-021-04100-5
关键词
Friedreich Ataxia; Iron-sulfur; Mitochondria; Oxidative stress; OXPHOS
资金
- CRUE-CSIC
- Springer Nature
- Association Francaise de l Ataxie de Friedreich - AFAF
- Ministerio de Economia y Empresa (MINECO, Spain) [SAF2017-83883-R]
Friedreich Ataxia is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin gene. The most common mutation is a GAA expansion in the first intron of the gene, resulting in decreased frataxin expression. By introducing a specific mutation into the murine Fxn gene, researchers have analyzed the consequences of this mutation in vivo. They found that mice with this mutation displayed low frataxin levels in all tissues, neurological deficits resembling those in FA patients, and mitochondrial alterations. The researchers concluded that the primary pathological mechanism underlying this mutation is frataxin deficiency, suggesting frataxin replacement therapies may benefit patients with this mutation.
Friedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene. The most prevalent mutation is a GAA expansion in the first intron of the gene causing decreased frataxin expression. Some patients present the GAA expansion in one allele and a missense mutation in the other allele. One of these mutations, FXNI154F, was reported to result in decreased content of mature frataxin and increased presence of an insoluble intermediate proteoform in cellular models. By introducing this mutation into the murine Fxn gene (I151F, equivalent to human I154F) we have now analyzed the consequences of this pathological point mutation in vivo. We have observed that FXNI151F homozygous mice present low frataxin levels in all tissues, with no evidence of insoluble proteoforms. Moreover, they display neurological deficits resembling those observed in FA patients. Biochemical analysis of heart, cerebrum and cerebellum have revealed decreased content of components from OXPHOS complexes I and II, decreased aconitase activity, and alterations in antioxidant defenses. These mitochondrial alterations are more marked in the nervous system than in heart, precede the appearance of neurological symptoms, and are similar to those observed in other FA models. We conclude that the primary pathological mechanism underlying the I151F mutation is frataxin deficiency, like in patients carrying GAA expansions. Therefore, patients carrying the I154F mutation would benefit from frataxin replacement therapies. Furthermore, our results also show that the FXNI151F mouse is an excellent tool for analyzing tissue-specific consequences of frataxin deficiency and for testing new therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据